AbbVie Company Profile (NYSE:ABBV)

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ABBV
  • CUSIP: 00287Y10
  • Web:
  • Market Cap: $115.41847 billion
  • Outstanding Shares: 1,591,540,000
Average Prices:
  • 50 Day Moving Avg: $71.63
  • 200 Day Moving Avg: $65.94
  • 52 Week Range: $55.06 - $75.04
  • Trailing P/E Ratio: 14.37
  • Foreward P/E Ratio: 11.08
  • P/E Growth: 0.91
Sales & Book Value:
  • Annual Revenue: $26.22 billion
  • Price / Sales: 4.41
  • Book Value: $3.14 per share
  • Price / Book: 23.12
  • Annual Dividend: $2.56
  • Dividend Yield: 3.5%
  • EBIDTA: $11.15 billion
  • Net Margins: 24.07%
  • Return on Equity: 148.83%
  • Return on Assets: 12.18%
  • Debt-to-Equity Ratio: 7.31%
  • Current Ratio: 1.76%
  • Quick Ratio: 1.60%
  • Average Volume: 5.53 million shs.
  • Beta: 1.51
  • Short Ratio: 5.37
Frequently Asked Questions for AbbVie (NYSE:ABBV)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, June 23rd. Investors of record on Friday, July 14th will be given a dividend of $0.64 per share on Tuesday, August 15th. This represents a $2.56 annualized dividend and a dividend yield of 3.53%. The ex-dividend date of this dividend is Wednesday, July 12th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has approved a stock repurchase plan on Sunday, April 9th 2017, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 5% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) issued its earnings results on Friday, January, 27th. The company reported $1.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.20. The company had revenue of $6.78 billion for the quarter, compared to analyst estimates of $6.92 billion. AbbVie had a net margin of 24.07% and a return on equity of 148.83%. The business's revenue for the quarter was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.13 earnings per share. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, July, 28th 2017. View Earnings Estimates for AbbVie.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

13 brokers have issued 12 month price targets for AbbVie's shares. Their predictions range from $60.00 to $94.00. On average, they anticipate AbbVie's stock price to reach $74.58 in the next year. View Analyst Ratings for AbbVie.

What are analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. According to Zacks Investment Research, "AbbVie’s key drug Humira is performing well and should continue to be driven by growing awareness, favorable clinical data, new indications and expansion into new markets. Moreover, Imbruvica has multi-billion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Investor focus will be on the stock with several late-stage data-readouts are expected in 2017. AbbVie’s shares outperformed the large-cap pharma industry so far this year. However, Viekira faces intense pricing and competitive pressure in the HCV market. Though Humira is doing well, the company is concerned about the product’s long-term prospects owing to the potential biosimilar competition. Estimates remained stable ahead of the company’s Q2 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters. " (7/13/2017)
  • 2. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
  • 3. Argus analysts commented, "strong" second quarter earnings print.The analysts noted that not only were AbbVie's results driven by sales of Humira and Imbruvica, but its pipeline also "strengthened" following the acquisition of Stemcentrix and a partnership with Boehringer Ingelheim for the commercial rights of a new immunology drug that is in a late stage trial.The analysts also stated that the earnings print confirmed Imbruvica's "rapid acceptance" which bodes well for future sales. Coupled with the Venclexta drug, AbbVie boasts two "powerful drugs" to treat first- and second-line CLL and other hematogical malignancies.Related Link: Investors Cheer AbbVie's Q2 Numbers, ForecastThe analysts also stated that AbbVie's stock is "attractively valued" at just 11.2x their 2017 earnings per share estimate, which is "well below" the average multiple of 14.5 of other companies under Argus' coverage.Finally, the analysts boosted their full-year 2016 adjusted earnings per share estimate to $4.84 from $4.80 and their 2017 earnings per share estimate to $5.95 from $5.90."The company has strengthened its product portfolio and pipeline through several deals over the past 12 months, and continues to post strong sales of Humira, aided by new indications," (8/8/2016)

Are investors shorting AbbVie?

AbbVie saw a drop in short interest in the month of July. As of July 14th, there was short interest totalling 20,721,827 shares, a drop of 15.1% from the June 30th total of 24,405,917 shares. Based on an average daily volume of 4,123,053 shares, the days-to-cover ratio is presently 5.0 days. Currently, 1.3% of the shares of the stock are sold short.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
  • William J. Chase, Executive Vice President, Chief Financial Officer
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
  • Carlos Alban, Executive Vice President - Commercial Operations
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
  • Timothy J. Richmond, Senior Vice President - Human Resources
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
  • Robert A. Michael, Vice President, Controller
  • Robert J. Alpern M.D., Independent Director

Who owns AbbVie stock?

AbbVie's stock is owned by many different of institutional and retail investors. Top institutional investors include US Bancorp DE (0.18%), Bank of Montreal Can (0.13%), APG Asset Management N.V. (0.10%), Chevy Chase Trust Holdings Inc. (0.09%), NN Investment Partners Holdings N.V. (0.09%) and National Pension Service (0.08%). Company insiders that own AbbVie stock include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Strs Ohio, Atalanta Sosnoff Capital LLC, Miller Howard Investments Inc. NY, Russell Investments Group Ltd., Armstrong Shaw Associates Inc. CT, Breton Hill Capital Ltd. and Exxonmobil Investment Management Inc. TX. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was purchased by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., NN Investment Partners Holdings N.V., ING Groep NV, Pennsylvania Trust Co, National Pension Service, GW&K Investment Management LLC, Manning & Napier Advisors LLC and Aperio Group LLC. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $72.59.

MarketBeat Community Rating for AbbVie (NYSE ABBV)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  548 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  826
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.54)
Consensus Price Target: $74.58 (2.75% upside)

Analysts' Ratings History for AbbVie (NYSE:ABBV)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017Credit Suisse GroupReiterated RatingNeutral$65.00 -> $74.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingHold$65.00 -> $66.00LowView Rating Details
7/17/2017Jefferies Group LLCReiterated RatingBuy$92.00 -> $94.00LowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
6/22/2017Societe GeneraleUpgradeHold -> BuyLowView Rating Details
5/17/2017BMO Capital MarketsReiterated RatingMarket Perform$66.00LowView Rating Details
3/11/2017Goldman Sachs Group, Inc. (The)UpgradeBuy -> Conviction-Buy$74.00 -> $80.00N/AView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016Citigroup Inc.DowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$82.00N/AView Rating Details
8/8/2016ArgusReiterated RatingBuy$85.00N/AView Rating Details
8/2/2016Barclays PLCReiterated RatingEqual Weight$68.00N/AView Rating Details
6/8/2016Morgan StanleyDowngradeOverweight -> Equal Weight$73.00 -> $65.00N/AView Rating Details
6/6/2016Cowen and CompanyDowngradeOutperform -> Market Perform$77.00 -> $70.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for AbbVie (NYSE:ABBV)
Earnings by Quarter for AbbVie (NYSE:ABBV)
Earnings History by Quarter for AbbVie (NYSE ABBV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2017$1.40N/AView Earnings Details
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.52 EPS
Next Year EPS Consensus Estimate: $6.55 EPS


Current Dividend Information for AbbVie (NYSE:ABBV)
Next Dividend:8/15/2017
Annual Dividend:$2.56
Dividend Yield:3.53%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:66.32% (Trailing 12 Months of Earnings)
46.38% (Based on This Year's Estimates)
39.08% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Dividend History by Quarter for AbbVie (NYSE ABBV)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 68.08%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.28View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.79View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
DateHeadline logoGilead Sciences Has 3 Available Options, but Only 1 Makes Sense - July 26 at 8:17 PM logoAbbVie's Long Shot At Proving Rova-T Doubters Wrong - Seeking Alpha - July 25 at 3:16 PM logoAbbVie Several Candidates to Replace Humira in the Pipeline - July 25 at 3:16 PM logoAbbVie Ordered To Pay $150 Mln In AndroGel Lawsuit - July 25 at 12:03 AM logoSeeger Weiss LLP Reports: Chicago Jury Finds AbbVie Fraudulently Marketed AndroGel to Injured Oregon Man; Awards $150 Million in Punitive Damages - July 25 at 12:03 AM logoAbbVie Ordered to Pay $150 Million in AndroGel Lawsuit - July 25 at 12:03 AM logoSeeger Weiss LLP Reports: Chicago Jury Finds AbbVie Fraudulently Marketed AndroGel to Injured Oregon Man ... - PR Newswire (press release) - July 24 at 7:01 PM logoAbbVie Ordered to Pay $150 Million Damages in 'Low-T' Trial - Bloomberg - July 24 at 7:01 PM logoAbbVie Ordered to Pay $150 Million Damages in ‘Low-T’ Trial - July 24 at 7:01 PM logoWhy Reata Pharmaceuticals Is Rallying 17.5% Today - July 24 at 7:01 PM logoU.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict - July 24 at 7:01 PM logo[$$] AbbVie Ordered to Pay $150 Million in AndroGel Lawsuit - July 24 at 7:01 PM logoThese 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet - July 23 at 3:15 PM logo3 Stocks That Are Absurdly Cheap Right Now - July 23 at 3:15 PM logoBetter Buy: AbbVie Inc. vs. Johnson & Johnson -- The Motley Fool - Motley Fool - July 22 at 8:19 PM logoBetter Buy: AbbVie Inc. vs. Johnson & Johnson - July 22 at 3:16 PM logoAbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store? - Nasdaq - Nasdaq - July 21 at 9:30 PM logoAbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store? - July 21 at 9:30 PM logoAbbVie Inc. (ABBV) Given Average Rating of "Buy" by Brokerages - July 21 at 4:59 PM logoAbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store? - July 21 at 4:28 PM logoAbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis - July 21 at 4:27 PM logoAbbVie Inc. (ABBV) to Release Quarterly Earnings on Friday - July 21 at 7:02 AM logoAbbVie loses bid to overturn $15 million Depakote injury verdict - Reuters - July 21 at 1:26 AM logoVetr Inc. Lowers AbbVie Inc. (ABBV) to Hold - July 21 at 12:44 AM logoCramer's charts reveal that technology isn't the only sector driving the rally - July 20 at 8:26 PM logoAbbVie Inc. (ABBV) Rating Reiterated by Credit Suisse Group - July 20 at 9:06 AM logoTop Marijuana Stocks that Pay Dividends - July 19 at 3:20 PM logoGilead's HCV Portfolio Receives a Boost With Vosevi Approval - July 19 at 3:20 PM logoGilead Sciences: Not a Game Changer - July 19 at 3:20 PM logoHow AbbVie Could Hammer Gilead's Hepatitis C Franchise - July 19 at 3:20 PM logoAbbVie Inc. (ABBV) Sees Large Decrease in Short Interest - July 19 at 7:04 AM logoCramer's charts reveal that technology isn't the only sector driving the rally - July 18 at 8:23 PM logoCramer's charts reveal that technology isn't the only sec... - July 18 at 8:23 PM logoThis Drug Bellwether's Sales Miss Actually Bodes Well For The Sector - July 18 at 3:21 PM logoCritical Analysis: Repligen Corporation (RGEN) and AbbVie (NYSE:ABBV) - July 18 at 9:41 AM logo'Stars Align' For These Biotechs To Crush Earnings Consensus - July 17 at 3:24 PM logoAbbVie Inc. (NYSE:ABBV) Receives "Hold" Rating from Deutsche Bank AG - July 17 at 1:44 PM logoProfessional Advisory Services Inc Buys Facebook Inc, TJX Inc, US Bancorp, Sells Verizon ... - July 14 at 10:12 PM logoAbbVie Inc (ABBV) Stock Isn't Done Charting New Highs Yet - - July 14 at 5:08 PM logoAbbVie Inc (ABBV) Stock Isn’t Done Charting New Highs Yet - July 14 at 5:08 PM logoAbbVie Inc (ABBV) Stock Isn’t Done Charting New Highs Yet - July 14 at 2:43 PM logo$6.92 Billion in Sales Expected for AbbVie Inc. (NYSE:ABBV) This Quarter - July 14 at 12:28 PM logoTraders Purchase Large Volume of Call Options on AbbVie (ABBV) - July 14 at 7:34 AM logoTop Stock Reports for Boeing, AbbVie & U.S. Bancorp - July 13 at 8:46 PM logoAbbVie Inc. (NYSE:ABBV) Lifted to "Hold" at Zacks Investment Research - July 13 at 4:52 PM logoAbbVie Inc. (NYSE:ABBV) Expected to Announce Earnings of $1.40 Per Share - July 12 at 6:29 PM logoAmgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label - July 12 at 3:16 PM logoThe Top Dividend-Growing Healthcare and Industrials Stocks - July 12 at 3:16 PM logoAbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2017 - Nasdaq - July 11 at 9:28 PM logoDividend Coverage: This Pharma Dividend Aristocrat has a Dividend Yield of 3.55%; Will Trade Ex-Dividend on July 12, 2017 - July 11 at 4:20 PM



AbbVie (ABBV) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff